MX2009013835A - Forma de dosis estabilizada de picoplatino. - Google Patents

Forma de dosis estabilizada de picoplatino.

Info

Publication number
MX2009013835A
MX2009013835A MX2009013835A MX2009013835A MX2009013835A MX 2009013835 A MX2009013835 A MX 2009013835A MX 2009013835 A MX2009013835 A MX 2009013835A MX 2009013835 A MX2009013835 A MX 2009013835A MX 2009013835 A MX2009013835 A MX 2009013835A
Authority
MX
Mexico
Prior art keywords
dosage form
stabilized picoplatin
picoplatin dosage
stabilized
picoplatin
Prior art date
Application number
MX2009013835A
Other languages
English (en)
Spanish (es)
Inventor
Ronald A Martell
David A Karlin
Original Assignee
Poniard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poniard Pharmaceuticals Inc filed Critical Poniard Pharmaceuticals Inc
Publication of MX2009013835A publication Critical patent/MX2009013835A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2009013835A 2007-06-27 2008-06-27 Forma de dosis estabilizada de picoplatino. MX2009013835A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US94663907P 2007-06-27 2007-06-27
US2738808P 2008-02-08 2008-02-08
US5507108P 2008-05-21 2008-05-21
PCT/US2008/008076 WO2009032034A2 (en) 2007-06-27 2008-06-27 Stabilized picoplatin dosage form

Publications (1)

Publication Number Publication Date
MX2009013835A true MX2009013835A (es) 2010-05-17

Family

ID=40429589

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013835A MX2009013835A (es) 2007-06-27 2008-06-27 Forma de dosis estabilizada de picoplatino.

Country Status (12)

Country Link
US (2) US20100215727A1 (enExample)
EP (1) EP2157864A4 (enExample)
JP (1) JP2010531877A (enExample)
KR (1) KR20100051797A (enExample)
CN (1) CN101801198A (enExample)
AU (1) AU2008295576A1 (enExample)
BR (1) BRPI0811816A2 (enExample)
CA (1) CA2691115A1 (enExample)
IL (2) IL202743A0 (enExample)
MX (1) MX2009013835A (enExample)
TW (1) TW200916094A (enExample)
WO (1) WO2009032034A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
WO2010132596A1 (en) * 2009-05-12 2010-11-18 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
WO2008097658A1 (en) * 2007-02-09 2008-08-14 Poniard Pharmaceuticals, Inc. Encapsulated picoplatin
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200920347A (en) * 2007-07-16 2009-05-16 Poniard Pharmaceuticals Inc Oral formulations for picoplatin
AU2009210654A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer
US20120148661A1 (en) * 2009-04-15 2012-06-14 Poniard Pharmaceuticals, Inc. High bioavailability oral picoplatin anti-cancer therapy
CN101804025B (zh) * 2010-03-31 2011-09-21 昆明贵研药业有限公司 甲啶铂的一种水溶液注射剂
CN102590385B (zh) * 2012-02-14 2013-09-11 昆明贵研药业有限公司 一种甲啶铂及其杂质的检测方法
US11090290B2 (en) * 2015-05-13 2021-08-17 Monopar Therapeutics, Inc. Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy
SI3393478T1 (sl) * 2015-12-23 2020-07-31 NuCana plc Kombinacijska terapija
CN106943343B (zh) * 2016-01-06 2020-05-12 山东新时代药业有限公司 一种甲啶铂注射液及其制备方法
CN107773538B (zh) * 2016-08-27 2022-09-13 鲁南制药集团股份有限公司 稳定的甲啶铂无菌冻干粉末及其制备工艺
CN117940164A (zh) * 2022-04-26 2024-04-26 石药集团中奇制药技术（石家庄）有限公司 米托蒽醌脂质体联合抗血管生成靶向药治疗卵巢癌的用途

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1432562A (en) * 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum co-ordination compounds
GB2060615B (en) * 1979-08-23 1983-06-22 Johnson Matthey Co Ltd Platinum-amine complexes
US4302446A (en) * 1979-10-02 1981-11-24 Bristol-Myers Company Pharmaceutical compositions
GR75317B (enExample) * 1980-09-03 1984-07-13 Johnson Matthey Plc
US4533502A (en) * 1983-02-22 1985-08-06 Rochon Fernande D Platinum (II) compounds and their preparation
DE3582961D1 (de) * 1984-06-27 1991-07-04 Johnson Matthey Plc Platinkoordinationsverbindungen.
US5082655A (en) * 1984-07-23 1992-01-21 Zetachron, Inc. Pharmaceutical composition for drugs subject to supercooling
KR900003457B1 (ko) * 1986-12-18 1990-05-19 시오노기세이야꾸 가부시끼가이샤 암민-지환식아민-백금 착화합물 및 항종양제
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB9105037D0 (en) * 1991-03-09 1991-04-24 Johnson Matthey Plc Improvements in chemical compounds
US5244991A (en) * 1991-10-15 1993-09-14 Phillips Petroleum Company Olefin polymerization process
ZA928771B (en) * 1991-11-15 1993-09-08 Smithkline Beecham Corp Combination chemotherapy
JP3633932B2 (ja) * 1992-04-01 2005-03-30 ザ ジョーンズ ホプキンズ ユニバーシティー スクール オブ メディシン 糞便試料から単離した哺乳類の核酸を検出する方法、およびその検出用試薬
SK279684B6 (sk) * 1993-06-14 1999-02-11 Janssen Pharmaceutica N.V. Tableta a spôsob jej výroby
US5624919A (en) * 1993-09-14 1997-04-29 The University Of Vermont And State Agricultural College Trans platinum (IV) complexes
GB9408218D0 (en) * 1994-04-26 1994-06-15 Johnson Matthey Plc Improvements in platinum complexes
AU2768295A (en) * 1994-07-11 1996-02-09 Hoechst Marion Roussel, Inc. Method of treating a neoplastic disease state by conjunctive therapy with 2'-fluoromethylidene derivatives and radiation or chemotherapy
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9502799D0 (en) * 1995-02-14 1995-04-05 Johnson Matthey Plc Improvements in platinum complexes
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
KR20000022226A (ko) * 1996-06-25 2000-04-25 그레이엄 브레레톤;레슬리 에드워즈 Hiv 치료에 사용하기 위한 vx478, 지도부딘, ftc 및(또는) 3tc를 포함하는 배합물
ATE252372T1 (de) * 1996-08-23 2003-11-15 Sequus Pharm Inc Liposome enthaltend cisplatin
DE19847618A1 (de) * 1998-10-15 2000-04-20 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
US6235782B1 (en) * 1998-11-12 2001-05-22 Rifat Pamukcu Method for treating a patient with neoplasia by treatment with a platinum coordination complex
DK1165576T3 (da) * 1999-04-13 2006-03-27 Anormed Inc Fremgangsmåde til fremstilling af amin-platin-komplekser
US6413953B1 (en) * 1999-04-13 2002-07-02 Anormed Inc. Pt(IV) antitumor agent
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US20020102301A1 (en) * 2000-01-13 2002-08-01 Joseph Schwarz Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
DE60032517T2 (de) * 2000-02-16 2007-10-04 Astellas Pharma Inc. Heilmittel gegen durch endothelin verursachte erkrankungen
AU2001246477A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
US20020156033A1 (en) * 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US6545010B2 (en) * 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
EE200200565A (et) * 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
US20020110601A1 (en) * 2000-03-31 2002-08-15 Roman Perez-Soler Antineoplastic platinum therapeutic method and composition
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
US6806289B1 (en) * 2000-07-14 2004-10-19 Stephen J. Lippard Coordination complexes, and methods for preparing by combinatorial methods, assaying and using the same
AU2001277711A1 (en) * 2000-08-11 2002-02-25 Sumitomo Pharmaceuticals Co. Ltd. Remedies for cisplatin-tolerant cancer
US6894049B1 (en) * 2000-10-04 2005-05-17 Anormed, Inc. Platinum complexes as antitumor agents
CA2326004A1 (en) * 2000-11-02 2002-05-02 Richard E. Jones Methods for treating cellular proliferative disorders
SE0004671D0 (sv) * 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
US6673370B2 (en) * 2001-05-15 2004-01-06 Biomedicines, Inc. Oxidized collagen formulations for use with non-compatible pharmaceutical agents
PT1416917E (pt) * 2001-08-06 2007-08-16 Astrazeneca Ab ''dispersão aquosa compreendendo nanopartículas estáveis de um triglicérido de cadeia média (mct) activo insolúvel em água e um do tipo excipiente''
US7265134B2 (en) * 2001-08-17 2007-09-04 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2005502653A (ja) * 2001-08-20 2005-01-27 トランセーヴ・インコーポレーテッド 肺ガンの治療方法
DE10141528B4 (de) * 2001-08-24 2006-08-10 Faustus Forschungs Cie. Translational Cancer Research Gmbh Platin(II)- und Platin(IV)-Komplexe und ihre Verwendung
US20030144312A1 (en) * 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
US20060078618A1 (en) * 2001-12-11 2006-04-13 Constantinides Panayiotis P Lipid particles and suspensions and uses thereof
AU2003220022A1 (en) * 2002-03-01 2003-09-16 Trustees Of Dartmouth College Compositions and methods for preventing sporadic neoplasia in colon
US20040010553A1 (en) * 2002-07-15 2004-01-15 International Business Machines Corporation Peer to peer location based services
TWI272273B (en) * 2002-07-16 2007-02-01 Sonus Pharma Inc Platinum compounds
AU2003258075A1 (en) * 2002-08-06 2004-02-23 Lyotropic Therapeutics, Inc. Lipid-drug complexes in reversed liquid and liquid crystalline phases
AU2002951833A0 (en) * 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
US8217010B2 (en) * 2002-10-24 2012-07-10 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
DE10256182A1 (de) * 2002-12-02 2004-06-24 Merck Patent Gmbh 2-Oxadiazolchromonderivate
US7109337B2 (en) * 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
ATE389650T1 (de) * 2003-04-30 2008-04-15 Merck Patent Gmbh Chromenonderivate
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
MXPA06011658A (es) * 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
EP1758887A1 (en) * 2004-05-14 2007-03-07 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
TW200600091A (en) * 2004-05-21 2006-01-01 Telik Inc Sulfonylethyl phosphorodiamidates
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
EP2027853A3 (en) * 2004-06-18 2011-01-05 Agennix USA Inc. Kinase inhibitors for treating cancers
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
JP2008513435A (ja) * 2004-09-22 2008-05-01 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US7807662B2 (en) * 2004-12-23 2010-10-05 University Of South Florida Platinum IV complex inhibitor
JP5106098B2 (ja) * 2005-02-28 2012-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド化合物の抗癌剤との新規併用
WO2006104668A2 (en) * 2005-03-11 2006-10-05 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of proliferative diseases
ES2493466T3 (es) * 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
CN101291658B (zh) * 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
WO2007056263A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
US20070190182A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056236A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070122350A1 (en) * 2005-11-30 2007-05-31 Transave, Inc. Safe and effective methods of administering therapeutic agents
US8143236B2 (en) * 2005-12-13 2012-03-27 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods
EP2004175A4 (en) * 2006-03-16 2010-12-15 Bionumerik Pharmaceuticals Inc COMPOUNDS AND FORMULATIONS FOR INCREASING THE EFFECT OF CANCER AND METHOD FOR THEIR USE
CA2655933C (en) * 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
KR20090094148A (ko) * 2006-12-20 2009-09-03 제이-씨 헬쓰 케어 리미티드 페길화 리포좀 독소루비신의 투여 방법
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
WO2008097658A1 (en) * 2007-02-09 2008-08-14 Poniard Pharmaceuticals, Inc. Encapsulated picoplatin
US7687487B2 (en) * 2007-04-19 2010-03-30 Bionumerik Pharmaceuticals, Inc. Camptothecin-analog with a novel, “flipped” lactone-stable, E-ring and methods for making and using same
WO2008150506A1 (en) * 2007-05-31 2008-12-11 Ascenta Therapeutics, Inc. Pulsatile dosing of gossypol for treatment of disease
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
TW200920347A (en) * 2007-07-16 2009-05-16 Poniard Pharmaceuticals Inc Oral formulations for picoplatin
ATE530169T1 (de) * 2007-09-28 2011-11-15 Bind Biosciences Inc Krebszellen-targeting mit nanopartikeln
AU2009210654A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer

Also Published As

Publication number Publication date
CA2691115A1 (en) 2009-03-12
IL251175A0 (en) 2017-04-30
US20100215727A1 (en) 2010-08-26
US20100178328A1 (en) 2010-07-15
KR20100051797A (ko) 2010-05-18
BRPI0811816A2 (pt) 2014-12-30
EP2157864A2 (en) 2010-03-03
TW200916094A (en) 2009-04-16
EP2157864A4 (en) 2013-09-11
JP2010531877A (ja) 2010-09-30
CN101801198A (zh) 2010-08-11
WO2009032034A3 (en) 2009-04-30
IL202743A0 (en) 2010-06-30
WO2009032034A2 (en) 2009-03-12
AU2008295576A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
WO2009032034A3 (en) Stabilized picoplatin dosage form
SG178952A1 (en) Chemical compounds
MX2010010647A (es) Proceso para preparar formulaciones de dabigatran para administracion oral.
PH12014500386A1 (en) Combination treatment for hepatitis c
NZ608673A (en) Therapeutic use of a tlr agonist and combination therapy
UA107112C2 (uk) Активатори розчинної гуанілатциклази
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
MX2011012122A (es) Derivados de tiofeno.
UA118025C2 (uk) Модулятор андрогенних рецепторів і його застосування
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
NZ593110A (en) pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
AU2011274192A8 (en) Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof
PH12013500473A1 (en) Triazine-oxadiazoles
MX2010009222A (es) Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos.
MX336071B (es) Formulaciones intravenosas de antagonistas de neurocinina 1.
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
UA105229C2 (uk) Фармацевтичний склад
EA201170527A1 (ru) Фармацевтические композиции, включающие соединения бороновой кислоты
MY162319A (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
UA103500C2 (uk) Сульфоксимінзаміщені анілінопіримідинові похідні як cdk-інгібітори, їх одержання й застосування як лікарських засобів
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
MX2009013501A (es) Compuestos piperidinicos y sus usos.
UA96753C2 (ru) Лекарственное средство, которое содержит фторхинолоны
TN2013000413A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
TN2009000275A1 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome

Legal Events

Date Code Title Description
FA Abandonment or withdrawal